#Biopharmaceuticals Market Share
Explore tagged Tumblr posts
Text
Exploring the Growth and Innovation in the Biopharmaceuticals Industry
The Biopharmaceuticals Market size is projected to reach a value of USD 401.46 billion in 2024, with expectations to grow to USD 577.87 billion by 2029, reflecting a CAGR of 7.56% over the forecast period from 2024 to 2029.
Market Size and Growth Potential
According to market research, the biopharmaceuticals market is experiencing substantial growth, spurred by a range of factors, including aging populations, increasing prevalence of chronic diseases, and innovations in bio-manufacturing technologies. The shift from traditional small-molecule drugs to complex, large-molecule biopharmaceuticals reflects the market’s evolution. Companies in this sector are investing heavily in research and development (R&D) to bring forward novel treatments that promise better patient outcomes with fewer side effects.
Key therapeutic areas driving the biopharmaceutical market include:
Oncology: Cancer therapies are a primary focus within biopharmaceuticals, as biologics offer new approaches to targeting and treating various cancer types. The use of monoclonal antibodies, for example, has transformed treatment strategies by enabling the immune system to recognize and attack cancer cells more effectively.
Autoimmune Diseases: Treatments for autoimmune disorders such as rheumatoid arthritis, psoriasis, and multiple sclerosis have also advanced with biopharmaceutical solutions, offering patients more effective, targeted relief through biologics that suppress or modulate immune responses.
Rare and Genetic Disorders: Gene and cell therapies represent revolutionary treatment options for rare and genetic disorders, allowing healthcare providers to correct or replace faulty genes directly. These therapies hold immense promise for conditions that previously lacked viable treatment options.
Technological Advances and R&D Investments
The industry’s growth is underpinned by continuous innovation in biotechnology, including advances in gene editing (e.g., CRISPR), next-generation sequencing, and bioprocessing techniques that make production more scalable and cost-effective. Leading companies and research institutions are pouring resources into R&D, resulting in a robust pipeline of promising new therapies. The acceleration of artificial intelligence and machine learning in drug discovery and development processes has also streamlined the identification of potential new drugs, increasing efficiency and success rates.
Conclusion
The biopharmaceuticals industry is poised for continued growth, offering transformative potential for treating and managing complex diseases. As companies leverage biotechnology innovations to create safer and more effective therapies, the market will see expanding opportunities and new applications in healthcare. While challenges remain, the biopharmaceutical sector’s commitment to advancing healthcare solutions marks it as a key player in the future of medicine.
For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence https://www.mordorintelligence.com/industry-reports/global-biopharmaceuticals-market-industry
#Biopharmaceuticals Market#Biopharmaceuticals Market Size#Biopharmaceuticals Market Share#Biopharmaceuticals Market Trends#Biopharmaceuticals Market Growth
0 notes
Text
Biopharmaceuticals Market - Forecast(2024 - 2030)
Biopharmaceuticals Market Overview
Biopharmaceuticals Market size is estimated to reach $532.2 billion by 2027, growing at a CAGR of 7.1% during the forecast period 2022-2027. Biopharmaceuticals are types of substances that can be produced with the use of living organisms, such as microorganisms and animal cells that are intentionally prepared for therapeutical use in pharmaceuticals. This technique is applied in the manufacturing of biotech vaccines, blood, and blood component, allergenic that have the capacity to induce allergies, body cells and tissues, living cells used in cell therapies, gene therapies, and recombinant therapeutic proteins. This is one of the most effective clinical treatment modalities for a broad range of diseases, including cancers and metabolic disorders. Biopharmaceuticals have transformed the treatment of inflammatory disorders such as psoriasis, multiple sclerosis, rheumatic diseases, inflammatory bowel diseases, and also disorders of growth hormones. As per the American Cancer Society, the estimated count of novel cancer cases diagnosed and cancer deaths in the U.S. In 2021 are 1.9 million and 608,570 respectively. The use of monoclonal antibodies for treating various conditions and the demand for Human Insulin is rapidly increasing. As a result, FDA also approved 79 therapeutics monoclonal antibodies (mAbs) in December 2019. Like mAbs, protein-based therapeutics such as protein drugs are also used in Biopharmaceuticals that help to repair or replace proteins like interferon in the human body.
The potential of Biopharmaceuticals to treat life-threatening diseases is set to drive the Biopharmaceuticals Market. The endorsement of more novel biopharmaceutical products and continued R&D are set to propel the growth of the Biopharmaceuticals Market during the forecast period 2022-2027. This represents the Biopharmaceuticals Industry Outlook.
0 notes
Text
Biopharmaceuticals Industry Drives High Growth Through Innovation In Cell And Gene Therapies
The biopharmaceuticals industry develops medicines from living cells and organisms to treat a wide range of medical conditions. Biopharmaceuticals, also known as biologics, include vaccines, blood components, allergenics, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins. They can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living cells or tissues. The global biopharmaceutical industry is increasingly focusing on new cell and gene therapies to treat cancer and genetic diseases. Cell therapy often uses stem cells to replace or repair damaged tissues and cells, while gene therapy aims to fix defects by manipulating genes inside patient's cells and tissues. Major biopharmaceutical companies are making substantial investments in R&D for cutting-edge cell and gene therapies with the potential to treat previously untreatable medical conditions. The global biopharmaceuticals Market is estimated to be valued at US$ 397.24 Bn in 2023 and is expected to exhibit a CAGR of 9.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: The growth of the global biopharmaceuticals market is driven significantly by continued innovation in cell and gene therapies. According to the report by CMI, biopharma companies invested over $100 billion globally in R&D for cell and gene therapies in 2021 alone. Cell therapies have shown promising results in cancer immunotherapy by leveraging the immune system to fight tumors. Additionally, gene therapies aim to treat genetic diseases such as hemophilia at their root cause by fixing the defective genes. The high success rate of recent gene therapy clinical trials is fueling further investments in this area. While cell and gene therapies offer potential cures, their development requires substantial funding and brings high risks. Overall, continued biomedical advances are critical to maximize the healthcare outcomes from the multi-billion dollar biopharma industry. SWOT Analysis Strength: The biopharmaceuticals market is dominated by large companies with widespread R&D facilities and huge financial resources. These large players hold a major share of the market and have strong brand recognition. Biopharmaceuticals have minimal side effects compared to traditional drugs. They can be customized for individual patients which improves treatment effectiveness. Weakness: Biopharmaceuticals have a lengthy and complex development process making them highly capital intensive. The development of biologics requires specialized expertise and infrastructure which increases costs significantly. Some biopharmaceuticals also have short shelf lives and require specialized storage and distribution networks. Opportunity: The rapidly aging global population is increasing the demand for therapies to treat chronic diseases. Biopharmaceuticals are increasingly being used to treat conditions like cancer, immunological disorders, and cardiovascular diseases. Developing economies in Asia Pacific and Latin America offer huge market potential due to rising healthcare expenditure. Threats: Price controls and drug reimbursement policies enacted by various governments pose pricing challenges. Stricter regulations for approval and safety monitoring also increase compliance costs. Expiry of patents for blockbuster drugs results in competition from cheaper biosimilars. Outsourcing of manufacturing and lax regulatory oversight in some nations threatens quality assurance. Key Takeaways The global biopharmaceuticals market growth is expected to witness high growth over the forecast period supported by rising demand for specialty drugs and biologics globally. The global biopharmaceuticals Market is estimated to be valued at US$ 397.24 Bn in 2023 and is expected to exhibit a CAGR of 9.4% over the forecast period 2023 to 2030.
The North American region currently dominates the market owing to advanced research capabilities and strong presence of leading players. However, Asia Pacific is emerging as the fastest growing regional market due to growing health awareness, increasing healthcare spending, and improving research infrastructure in countries like China, India, and South Korea. The presence of contract manufacturing hubs in India and China coupled with improving research capabilities is attracting significant investments from global pharmaceutical giants. Furthermore, rising affluence, increased awareness, and favorable government policies are driving healthcare spending upwards in major Asian economies. Countries like India, China, South Korea, and Singapore are actively promoting the development of biologics and biosimilars. Key players Key players operating in the biopharmaceuticals market are Accenture, Teleperformance SE, Infosys Limited (Infosys BPM), WNS (Holdings) Ltd., HCL Technologies Limited, AMDOCS, CBRE Group Inc., Sodexo, NCR Corporation, TTEC Holdings, Inc., Wipro Limited, and Capgemini. These companies offer integrated services and solutions across the value chain to help pharmaceutical companies optimize operations and reduce costs.
Get more insights on this topic: https://www.newsstatix.com/biopharmaceuticals-market-industry-insights-trends-biopharmaceuticals-market/ Explore more information on this topic, Please visit: https://filmik.in/molecular-cytogenetics-the-future-of-genomic-research/
#Biopharmaceuticals#Biopharmaceuticals Market#Biopharmaceuticals Market size#Biopharmaceuticals Market share#Biopharmaceuticals Market demand#Biopharmaceuticals Market analysis
0 notes
Link
#market research future#biopharmaceutical excipients#biopharmaceuticals market size#biopharmaceutical market trend#pharmaceutical excipient share
0 notes
Text
U.S. Biopharmaceutical Third-party Logistics Market Outlook On The Basis Of Supply Chain, Service, Product Type, Region And Forecast From 2022 to 2030: Grand View Research Inc.
U.S. Biopharmaceutical Third-party Logistics Market Outlook On The Basis Of Supply Chain, Service, Product Type, Region And Forecast From 2022 to 2030: Grand View Research Inc.
San Francisco, 2 Jan 2023: The Report U.S. Biopharmaceutical Third-party Logistics Market Size, Share & Trends Analysis Report By Supply Chain (Cold Chain, Non-cold Chain), By Service, By Product Type (Specialty Drug), And Segment Forecasts, 2022 – 2030 The U.S. biopharmaceutical third-party logistics market size is expected to reach USD 87.2 billion by 2030, expanding at a CAGR of 7.3% over the…
View On WordPress
#U.S. Biopharmaceutical Third-party Logistics Market#U.S. Biopharmaceutical Third-party Logistics Market 2030#U.S. Biopharmaceutical Third-party Logistics Market Revenue#U.S. Biopharmaceutical Third-party Logistics Market Share#U.S. Biopharmaceutical Third-party Logistics Market Size
0 notes
Text
Biopharmaceutical CMO Market SWOT analysis, Growth, Share, Size and Demand outlook by 2031 | Samsung Biologics, Patheon, Lonza AG, WuXi Biologics, AbbVie Inc., Binex Co., Ltd.
Global Biopharmaceutical CMO Market report from Global Insight Services is the single authoritative source of intelligence on Biopharmaceutical CMO Market . The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters’ and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types, applications, and geographies. Report also includes comprehensive analysis of key issues, trends and drivers, restraints and challenges, competitive landscape, as well as recent events such as M&A activities in the market.
A Contract Manufacturing Organization (CMO), also known as a Biopharmaceutical CMO, is a company that provides manufacturing and other services to the pharmaceutical and biotechnology industries. CMOs are an important part of the pharmaceutical supply chain, and they play a vital role in bringing new drugs and therapies to market.
Get Free Sample Copy of This Report –https://www.globalinsightservices.com/request-sample/GIS21593/
Key Trends
The key trends in Biopharmaceutical CMO technology are:
1. The use of biotechnology to develop new drugs and therapies.
2. The use of cell culture and fermentation technologies to produce biopharmaceuticals.
3. The use of monoclonal antibodies and other protein-based drugs.
4. The use of nucleic acid-based drugs and gene therapy.
Key Drivers
The biopharmaceutical CMO market is driven by the increasing demand for biopharmaceuticals, the need for specialized manufacturing facilities, and the increasing number of biopharmaceutical companies. The biopharmaceutical industry is growing at a rapid pace, and the number of biopharmaceutical companies is increasing. This is resulting in an increased demand for CMOs. CMOs are specialized manufacturing facilities that are required for the production of biopharmaceuticals. They are required to meet the stringent quality standards set by the FDA. The increasing number of biopharmaceutical companies is resulting in an increased demand for CMOs.
The biopharmaceutical CMO market is facing a number of key restraints and challenges. Firstly, the market is highly competitive and there are a large number of players operating in the space. This makes it difficult for new entrants to gain a foothold in the market. Secondly, the market is capital intensive and requires significant investment in research and development. This is a major barrier for small and medium sized companies. Thirdly, the regulatory environment is constantly changing and this makes it difficult for companies to keep up with the latest regulations. Finally, the market is reliant on a small number of key customers and this makes it difficult to diversify revenue streams.
Market Segments
The biopharmaceutical CMO market report is bifurcated on the basis of product, source, service, and region. On the basis of product, it is segmented into biologics and biosimilars. Based on source, it is analyzed across mammalian and non-mammalian. By service, it is categorized into contract manufacturing, process development, packaging, and others. Region-wise, it is studied across North America, Europe, Asia-Pacific, and rest of the World.
Key Player
The biopharmaceutical CMO market report includes players such as Toyobo Co., Ltd., Samsung Biologics, Patheon, Lonza AG, WuXi Biologics, AbbVie Inc., Binex Co., Ltd., JRS Pharma, Biomeva GmbH, and ProBioGen AG.
With Global Insight Services, you receive:
10-year forecast to help you make strategic decisions
In-depth segmentation which can be customized as per your requirements
Free consultation with lead analyst of the report
Excel data pack included with all report purchases
Robust and transparent research methodology
Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1–833–761–1700Website:https://www.globalinsightservices.com/
#Biopharmaceutical CMO Market#Biopharmaceutical CMO Market share#Biopharmaceutical CMO Market size#Biopharmaceutical CMO Market trend#Biopharmaceutical CMO Market growth#Biopharmaceutical CMO Market demand
0 notes
Text
Magnetic Beads Market Outlook: World Approaching Demand & Growth Prospect 2022-2027
Global Magnetic Beads Market Report from AMA Research highlights deep analysis on market characteristics, sizing, estimates and growth by segmentation, regional breakdowns & country along with competitive landscape, players market shares, and strategies that are key in the market. The exploration provides a 360° view and insights, highlighting major outcomes of the industry. These insights help the business decision-makers to formulate better business plans and make informed decisions to improved profitability. In addition, the study helps venture or private players in understanding the companies in more detail to make better informed decisions.
Major Players in This Report Include Thermo Fisher Scientific Inc (United States),Merck KGaA, Darmstadt (Germany),Polysciences, Inc. (United States),Qiagen (Germany),MagQu Co. Ltd. (Taiwan),FUJIFILM Wako Pure Chemical Corporation (Japan),Takara Bio Inc. (Japan),Spherotech Inc (United States),Cube Biotech GmbH (Germany),Lab on a Bead AB (Sweden)
Magnetic beads & particles are used as carriers of antibodies, antigens, catalyzers, proteins as well as nucleic acids, allowing action on viruses, cells, bacteria, & other biological entities. Magnetic beads are an ultimate tool for immobilizing molecules such as proteins or nucleic acids on a solid phase. They can be additionally used in many applications. This magnetic bead separation process is an efficient, rapid, clean which many scientists are using to substitute centrifugation, filtration, as well as separation techniques. These are used for immunoprecipitation applications. These ensure the rapid & reproducible isolation of proteins. Market Drivers Growing Number of Life Sciences Research Activities
Rising Need to Identify Antigens That Are Related With Autoimmune Diseases
High Demand in The Biopharmaceuticals Field Involving The Application, Opportunities For New Innovation in The Field of Life Science
Opportunities Growing Genomics & Proteomics Research with the Increasing Adoption of Immunoprecipitation in the Coming Years
Growing Funding for Cell Based R&D by Government and Biotechnology companies
Challenges Quality Concerns over Research Antibodies
The Magnetic Beads market study is being classified by Application (Human Cell Separation, Animal cell separation (clinical study), Secondary cell separation), End Users (Healthcare Facilities (Hospitals, Clinics, and Others), Individual Pathology Labs, Research Institutes, Others), Magnetic Beads Size (Small beads (1-10 µm), Medium beads (20-40 µm), Large beads (70-120 µm)), Isolation Technique (Positive, Negative, Others (Depletion, and Others)) Presented By
AMA Research & Media LLP
2 notes
·
View notes
Text
Clinical Trial Supplies Industry 2030 Driving Factors, Future Trends, Size & Key Vendors
The global clinical trial supplies market was valued at approximately USD 2.58 billion in 2023 and is forecasted to grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2030. This growth is attributed to the increasing globalization of clinical trials and a rise in the number of biologics and biosimilar drugs being tested. The biopharmaceutical industry is also experiencing greater adoption of supply chain management systems aimed at improving operational efficiency and managing the pressures of high R&D costs. Supplies for clinical trials make up a substantial portion of total R&D spending, and these efficiencies are expected to propel market expansion in the coming years. In particular, the growing prevalence of biologics and temperature-sensitive drugs in clinical trials highlights the need for effective supply management.
Currently, the market is in a medium growth stage, and its expansion rate is accelerating. A defining feature of the clinical trial supplies market is its high level of innovation, as advancements in trial equipment, including cutting-edge imaging systems, monitoring tools, and diagnostic devices, are enhancing trial efficiency. This trend in innovation is driving greater demand for clinical trial supplies.
The market has also seen a moderate level of merger and acquisition (M&A) activity among leading companies. Many companies seek to provide comprehensive solutions for trial sponsors by acquiring specialized firms or expanding their service portfolios. With clinical trials taking place on a global scale, companies are extending their geographic reach to conduct trials across diverse regions, which enhances their market positioning.
The clinical trial supplies market operates under stringent regulations, enforced by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to protect participant safety and rights. This regulatory environment encourages companies to establish a presence in multiple regions to meet the varying requirements. Expanding regionally also helps companies streamline operations and optimize resources to address regulatory compliance and logistical needs in different countries.
Gather more insights about the market drivers, restrains and growth of the Clinical Trial Supplies Market
Regional Insights:
North America Clinical Trial Supplies Market Trends
In 2023, North America held the largest market share, representing approximately 55.49% of the global clinical trial supplies market. This region conducts the highest volume of clinical trials worldwide, which significantly drives demand for trial supplies. Additionally, North America is home to many leading companies in this industry, along with high levels of technological penetration, which contribute to its market dominance.
United States
In the United States, the clinical trial supplies market is projected to grow at a substantial rate over the coming years. The presence of major contract research organizations (CROs), such as Quintiles, Covance, and PAREXEL International Corporation, further bolsters the market’s growth. However, there is a growing trend of shifting clinical trial sites outside the U.S. due to rising R&D costs and patient recruitment expenses. This shift is increasing the demand for cost-effective clinical supplies, thereby boosting market growth in emerging economies.
Asia Pacific Clinical Trial Supplies Market Trends
Asia Pacific is expected to be one of the fastest-growing regions in the clinical trial supplies market due to significant growth in clinical research. Key drivers for this regional expansion include lower per-patient costs and a diverse patient pool, which enhances recruitment efficiency. These factors make Asia Pacific an attractive region for clinical trials, contributing to the global market’s growth.
China
China, in particular, presents substantial growth opportunities for clinical trial supply companies due to its large, diverse patient population and expanding pharmaceutical sector. However, logistics and supply chain challenges in the country have deterred some biopharmaceutical companies from conducting trials there. China accounts for over 27% of global clinical trials as of 2023 and has shown strong growth over the past five years. To address these logistical challenges and capitalize on the market potential, companies like Catalent Pharma Solutions are entering the Chinese market, which is expected to further drive growth in the country’s clinical trial supplies sector.
Browse through Grand View Research's Category Medical Devices Industry Research Reports.
The global 3D ultrasound market size was estimated at USD 3.73 billion in 2024 and is projected to grow at a CAGR of 7.8% from 2025 to 2030.
The global lancets market size was valued at USD 5.90 billion in 2024 and is projected to grow at a CAGR of 7.7% from 2025 to 2030.
Key Companies & Market Share Insights
Leading companies in the clinical trial supplies market are adopting inorganic growth strategies, such as mergers, acquisitions, and partnerships, to strengthen their market positions. For example, in March 2023, Calyx, a provider of eClinical regulatory services, introduced Calyx Supply, a forecasting service designed to predict clinical trial supply needs through simulation and statistical design. Similarly, in April 2021, Catalent expanded its clinical supply services capabilities at its Philadelphia facility to support clients working on cell and gene therapies.
These strategic expansions and innovations underscore the competitive landscape of the clinical trial supplies market. By investing in enhanced capabilities and broadening their service offerings, key players are positioning themselves to meet the growing demands of a global clinical trial landscape characterized by a diverse range of drug types, regulatory requirements, and logistical challenges.
Key Clinical Trial Supplies Companies
Almac Group
Biocair
Catalent Inc.
KLIFO
Movianto
PCI Pharma Services
Sharp Services, LLC
Thermo Fischer Scientific Inc.
Marken
PAREXEL International Corporation
Order a free sample PDF of the Clinical Trial Supplies Market Intelligence Study, published by Grand View Research.
0 notes
Text
Clinical Trial Supplies Market Segments by Application 2030
The global clinical trial supplies market was valued at approximately USD 2.58 billion in 2023 and is forecasted to grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2030. This growth is attributed to the increasing globalization of clinical trials and a rise in the number of biologics and biosimilar drugs being tested. The biopharmaceutical industry is also experiencing greater adoption of supply chain management systems aimed at improving operational efficiency and managing the pressures of high R&D costs. Supplies for clinical trials make up a substantial portion of total R&D spending, and these efficiencies are expected to propel market expansion in the coming years. In particular, the growing prevalence of biologics and temperature-sensitive drugs in clinical trials highlights the need for effective supply management.
Currently, the market is in a medium growth stage, and its expansion rate is accelerating. A defining feature of the clinical trial supplies market is its high level of innovation, as advancements in trial equipment, including cutting-edge imaging systems, monitoring tools, and diagnostic devices, are enhancing trial efficiency. This trend in innovation is driving greater demand for clinical trial supplies.
The market has also seen a moderate level of merger and acquisition (M&A) activity among leading companies. Many companies seek to provide comprehensive solutions for trial sponsors by acquiring specialized firms or expanding their service portfolios. With clinical trials taking place on a global scale, companies are extending their geographic reach to conduct trials across diverse regions, which enhances their market positioning.
The clinical trial supplies market operates under stringent regulations, enforced by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to protect participant safety and rights. This regulatory environment encourages companies to establish a presence in multiple regions to meet the varying requirements. Expanding regionally also helps companies streamline operations and optimize resources to address regulatory compliance and logistical needs in different countries.
Gather more insights about the market drivers, restrains and growth of the Clinical Trial Supplies Market
Regional Insights:
North America Clinical Trial Supplies Market Trends
In 2023, North America held the largest market share, representing approximately 55.49% of the global clinical trial supplies market. This region conducts the highest volume of clinical trials worldwide, which significantly drives demand for trial supplies. Additionally, North America is home to many leading companies in this industry, along with high levels of technological penetration, which contribute to its market dominance.
United States
In the United States, the clinical trial supplies market is projected to grow at a substantial rate over the coming years. The presence of major contract research organizations (CROs), such as Quintiles, Covance, and PAREXEL International Corporation, further bolsters the market’s growth. However, there is a growing trend of shifting clinical trial sites outside the U.S. due to rising R&D costs and patient recruitment expenses. This shift is increasing the demand for cost-effective clinical supplies, thereby boosting market growth in emerging economies.
Asia Pacific Clinical Trial Supplies Market Trends
Asia Pacific is expected to be one of the fastest-growing regions in the clinical trial supplies market due to significant growth in clinical research. Key drivers for this regional expansion include lower per-patient costs and a diverse patient pool, which enhances recruitment efficiency. These factors make Asia Pacific an attractive region for clinical trials, contributing to the global market’s growth.
China
China, in particular, presents substantial growth opportunities for clinical trial supply companies due to its large, diverse patient population and expanding pharmaceutical sector. However, logistics and supply chain challenges in the country have deterred some biopharmaceutical companies from conducting trials there. China accounts for over 27% of global clinical trials as of 2023 and has shown strong growth over the past five years. To address these logistical challenges and capitalize on the market potential, companies like Catalent Pharma Solutions are entering the Chinese market, which is expected to further drive growth in the country’s clinical trial supplies sector.
Browse through Grand View Research's Category Medical Devices Industry Research Reports.
The global 3D ultrasound market size was estimated at USD 3.73 billion in 2024 and is projected to grow at a CAGR of 7.8% from 2025 to 2030.
The global lancets market size was valued at USD 5.90 billion in 2024 and is projected to grow at a CAGR of 7.7% from 2025 to 2030.
Key Companies & Market Share Insights
Leading companies in the clinical trial supplies market are adopting inorganic growth strategies, such as mergers, acquisitions, and partnerships, to strengthen their market positions. For example, in March 2023, Calyx, a provider of eClinical regulatory services, introduced Calyx Supply, a forecasting service designed to predict clinical trial supply needs through simulation and statistical design. Similarly, in April 2021, Catalent expanded its clinical supply services capabilities at its Philadelphia facility to support clients working on cell and gene therapies.
These strategic expansions and innovations underscore the competitive landscape of the clinical trial supplies market. By investing in enhanced capabilities and broadening their service offerings, key players are positioning themselves to meet the growing demands of a global clinical trial landscape characterized by a diverse range of drug types, regulatory requirements, and logistical challenges.
Key Clinical Trial Supplies Companies
Almac Group
Biocair
Catalent Inc.
KLIFO
Movianto
PCI Pharma Services
Sharp Services, LLC
Thermo Fischer Scientific Inc.
Marken
PAREXEL International Corporation
Order a free sample PDF of the Clinical Trial Supplies Market Intelligence Study, published by Grand View Research.
0 notes
Text
Biopharmaceutical Contract Manufacturing Market Growth, Size & Share by 2033
Biopharmaceutical Contract Manufacturing Market Overview
The Global Biopharmaceutical Contract Manufacturing Market has seen continuous development in the past couple of years and is anticipated to grow much further during the forecast period. The exploration introduces a total evaluation of the Biopharmaceutical Contract Manufacturing Market and contains Future patterns, Current Growth Factors, mindful sentiments, certainties, chronicled information, and factually bolstered and industry-approved market information.
According to Straits Research, the global Biopharmaceutical Contract Manufacturing market size was valued at USD 17.20 Billion in 2022. It is projected to reach from USD XX Billion in 2023 to USD 26.46 Billion by 2031, growing at a CAGR of 4.9% during the forecast period (2023–2031).
After identifying promising candidates, they undergo extensive testing and optimization to enhance their effectiveness, safety, and pharmacokinetic properties. This entire process of Biopharmaceutical Contract Manufacturing Market may take several years and necessitates collaboration between scientists from diverse fields such as chemistry, biology, and pharmacology. Irrespective of the challenges encountered during Biopharmaceutical Contract Manufacturing Market, it has the potential to revolutionize lives by providing new treatments for various diseases.
Request Sample Report of Global Biopharmaceutical Contract Manufacturing Market @ https://straitsresearch.com/report/biopharmaceutical-contract-manufacturing-market/request-sample
Competitive Analysis
0 notes
Text
Strategic Market Trends Shaping the Future of Exocrine Pancreatic Insufficiency Solutions
Etanercept is a biopharmaceutical drug commonly used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and ankylosing spondylitis. As a biologic, it functions by targeting and inhibiting tumor necrosis factor (TNF), a protein that plays a role in causing inflammation in the body. By blocking TNF, Etanercept helps reduce symptoms like joint pain, swelling, and skin inflammation, which are prevalent in autoimmune conditions. The Etanercept market is experiencing growth due to the increasing prevalence of these diseases globally, alongside advancements in biologic treatments, which have proven to be effective for patients who do not respond well to traditional drugs.
The Etanercept Market Size was projected to be 17.98 (USD Billion) in 2022 based on MRFR analysis. By 2032, it is anticipated that the Etanercept Market Industry would have grown from 18.93 billion USD in 2023 to 30.1 billion USD. Throughout the forecast period (2024–2032), the Etanercept Market CAGR (growth rate) is anticipated to be approximately 5.29%.
Market Size of Etanercept
The market size for Etanercept has shown significant growth over the past decade, driven by the rising demand for biologic drugs and the expanding patient base of autoimmune conditions. The global Etanercept market size was estimated in billions of dollars, with projections indicating continued growth. Key regions driving this growth include North America, where advanced healthcare infrastructure and higher diagnosis rates contribute to higher Etanercept consumption, as well as regions in Asia-Pacific, where an increase in healthcare spending and awareness of autoimmune diseases is opening new market opportunities.
Etanercept Share in the Biologic Drug Market
Etanercept occupies a significant share within the biologic drug market. It is one of the leading biologics used for autoimmune diseases, competing with other TNF inhibitors and newer classes of biologic drugs. The presence of Etanercept biosimilars has diversified the market, leading to increased accessibility and competition, which helps expand its overall market share. As biosimilar drugs grow in acceptance globally, Etanercept’s share continues to be influenced by factors like pricing and the competitive landscape with alternative biologics. However, it remains a preferred treatment option for physicians and patients, maintaining its strong position in the global market.
Etanercept Analysis: Market Dynamics
The analysis of the Etanercept market reveals several dynamic factors that influence its growth and adoption. Key drivers include the rise in autoimmune disease cases, improved access to healthcare, and technological advances in drug production. Additionally, regulatory support for biologics and biosimilars contributes to the growth potential for Etanercept. However, factors like high costs associated with biologic drugs, strict regulatory requirements, and competition from alternative therapies can pose challenges. The Etanercept market analysis also indicates a trend toward patient-centric approaches, with ongoing research into more effective administration methods and dosage adjustments tailored to individual needs.
Etanercept Trends Shaping the Future Market
Emerging trends in the Etanercept market reflect the evolving healthcare landscape and technological advancements. Notably, the rise of biosimilars is a trend shaping Etanercept’s market, as it makes the drug more affordable and accessible. Another trend is the increasing focus on personalized medicine, allowing healthcare providers to tailor treatment with Etanercept based on individual patient factors. Additionally, advancements in drug delivery methods, such as self-injection devices, enhance patient convenience. Telemedicine and remote monitoring also support Etanercept adherence and usage by enabling better patient-doctor communication.
Reasons to Buy Etanercept Market Reports
Comprehensive Market Insights: Reports provide a detailed understanding of Etanercept market size, share, trends, and growth projections, offering crucial information for decision-making.
Competitive Analysis: Access to analysis on major players, emerging competitors, and market dynamics that influence Etanercept’s market position.
Trend Forecasting: Reports offer insights into emerging trends, including advancements in biosimilars, telemedicine, and personalized treatments.
Regional Market Breakdown: Detailed data on regional differences in Etanercept demand, providing insights into market opportunities across North America, Europe, and Asia-Pacific.
Investment Guidance: Insights on market drivers and potential challenges assist investors and stakeholders in making informed financial decisions.
Recent Developments in Etanercept Market
Recent developments in the Etanercept market highlight advancements in biosimilar approvals, which broaden access to treatment and reduce costs. Some pharmaceutical companies have introduced biosimilars in key markets, which could lower the price of Etanercept therapy, making it more accessible for patients. Additionally, research has continued to focus on improving Etanercept’s efficacy and safety profile, with some clinical trials exploring combination therapies with other biologics to enhance treatment outcomes. Digital health tools have also emerged, allowing for better monitoring of Etanercept usage and patient adherence, reflecting the shift towards integrated healthcare solutions. These innovations indicate an evolving market with new growth opportunities in the coming years.
Related repots:
autologous stem cell therapies market
antacid market
artificial intelligence in pharmaceutical market
artificial intelligence medical diagnostics market
Top of Form
Bottom of Form
0 notes
Text
Cleanroom Technology Market: Regional Analysis and Growth Opportunities
The global cleanroom technology market was valued at approximately USD 6.90 billion in 2022 and is projected to experience steady growth at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2030. This growth can be largely attributed to several key factors, including an increase in research and development activities, a rise in the prevalence of chronic diseases, and the growing demand for advanced electronic components. The market's expansion is being driven by the increasing need for contamination-free environments across a variety of industries such as biotechnology, electronics, healthcare, and pharmaceuticals.
As industries place a higher emphasis on regulatory compliance and stringent quality control, cleanroom technology has become indispensable. These environments play a critical role in ensuring patient safety and maintaining the integrity of products. Additionally, the growing number of regulations in sectors like healthcare and pharmaceuticals is compelling businesses to invest in cleanroom technology to meet these standards and remain compliant.
Technological innovations, including the integration of automation and robotics, are significantly enhancing the efficiency and functionality of cleanrooms, contributing to the market's growth. The importance of cleanroom technology is particularly evident in pharmaceutical manufacturing, which is seeing increasing global healthcare spending, as well as a growing focus on biopharmaceuticals and personalized medicine.
Gather more insights about the market drivers, restrains and growth of the Cleanroom Technology Market
Regional Insights
North America
North America dominated the global cleanroom technology market in 2022, capturing a significant market share of 37.8%. The United States was a major contributor to this regional leadership. The growth in North America is largely driven by stringent regulatory standards and a strong focus on maintaining high-quality manufacturing processes. Many biotechnology and pharmaceutical companies in the region rely heavily on controlled environments for research, product development, and production. A key factor fueling demand for cleanroom technology in North America is the booming electronics industry, especially the semiconductor manufacturing sector, which requires contamination-free environments for high-precision production.
Technological advancements, particularly the integration of automation and smart technologies, have further accelerated the growth of the cleanroom technology market in North America. These innovations improve efficiency and compliance, making cleanroom solutions more effective and adaptable. The region's commitment to continuous improvement in cleanroom design, equipment, and consumables helps meet the evolving demands of various industries. As innovation and regulatory compliance remain top priorities, North America's cleanroom technology market is expected to grow steadily in the coming years.
Asia Pacific
Asia Pacific is projected to experience the fastest growth in the cleanroom technology market, with a compound annual growth rate (CAGR) of 6.8% from 2023 to 2030. This growth is driven by several key factors, including rapid industrialization, significant investments in healthcare infrastructure, and the expansion of the electronics and pharmaceutical industries. Countries such as China, India, Japan, and South Korea are major contributors to the demand for cleanrooms, as they aim to meet stringent cleanliness and contamination control standards in production processes.
The region's dedication to technological advancements and its proactive adoption of cleanroom solutions to comply with international regulatory standards position Asia Pacific as a critical player in the global market. The cleanroom technology market in this region is expected to continue its strong growth trajectory, as industries prioritize contamination prevention and quality control to meet increasingly complex regulatory requirements. The integration of advanced technologies, like automation and smart systems, further supports the region's expansion, making it a key growth hub for the cleanroom industry.
Browse through Grand View Research's HVAC & Construction Industry Research Reports.
• The global data center cooling market size was estimated at USD 18.65 billion in 2023 and is expected to grow at a compounded annual growth rate (CAGR) of 16.8% from 2024 to 2030.
• The global construction robots market size was valued at USD 1,028.6 million in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 17.5% from 2023 to 2030.
Key Companies & Market Share Insights
The cleanroom technology market is characterized by both well-established industry leaders and emerging companies, creating a competitive landscape that fosters innovation.
Key players in the market include:
• Advanced Technology Group
• CIMTechniques (SmartScan Technologies)
• Cleanrooms By United
• Angstrom Technology
• Elsisan (YI-BA Engineering. Ltd. Sti.)
• HEMCO Corporation
• Kojair Tech Oy
• Spetec GmbH
• Terra Universal Inc.
• Thomas Scientific
Order a free sample PDF of the Cleanroom Technology Market Intelligence Study, published by Grand View Research.
#Cleanroom Technology Market#Cleanroom Technology Market Analysis#Cleanroom Technology Market Report#Cleanroom Technology Market Regional Insights
0 notes
Text
Biopharmaceutical CMO And CRO Market Is Estimated To Witness High Growth Owing To Increasing Demand For Outsourcing
Biopharmaceutical CMOs and CROs provide services like clinical trial management, data management, medical writing, clinical monitoring to biopharmaceutical and biotechnology companies. They help reduce development costs and improve productivity. With rise in complex drug development projects, outsourcing non-core functions have become essential.
The global biopharmaceutical CMO and CRO market is estimated to be valued at US$ 41.71 Mn in 2024 and is expected to exhibit a CAGR of 5.0% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: One of the key drivers for the growth of the biopharmaceutical CMO and CRO market is the increasing demand for outsourcing from biopharmaceutical companies. Due to high costs associated with drug development and pricing pressures, biopharma companies are increasingly outsourcing non-core activities like clinical trials to CROs and manufacturing to CMOs. This allows them to focus on drug discovery and commercialization while reducing fixed costs. Additionally, biopharmaceutical CMOs and CROs have capabilities across diverse therapeutic areas and expertise in handling complex projects involving novel biologics, vaccines, and cell and gene therapies. Their specialized expertise and economies of scale help accelerate development timelines and bring down costs for biopharma sponsors. SWOT Analysis Strength: The biopharmaceutical CMO and CRO market has experienced strong growth in recent years due to the increasing demand for biologics. CMOs provide services to drug makers from drug development to commercial manufacturing which helps biopharma companies focus on drug discovery. CROs help biopharma companies by outsourcing various research functions like preclinical and clinical trials which reduces operational costs. Weakness: CMOs and CROs face significant compliance and regulatory challenges to meet stringent manufacturing standards and quality controls set by regulatory agencies. Any issues with quality can damage reputation and business. Outsourcing clinical research also risks loss of control and intellectual property exposure. Opportunity: The growth of the biologics market and rising demand for personalized medicines is driving significant opportunity for CMOs and CROs. Emerging biotech companies also lack manufacturing capabilities and rely on CMOs. CROs can tap into the market for clinical trials outsourcing. Asia Pacific region offers lower costs that can boost outsourcing. Threats: Changing regulations and trade policies can disrupt operations and supply chains. Increasing M&A activity among CMOs and CROs leads to consolidation reducing client choice. Intense competition limits pricing power and pressure to diversify service offerings. Key Takeaways The global biopharmaceutical CMO and CRO market size is expected to witness high growth driven by the expanding biologics industry. The market size is projected to reach US$ 41.71 Mn in 2024 from US$ 31.13 Mn in 2021, registering a CAGR of 5.0% during the forecast period. Regional analysis:
North America currently dominates due to presence of major pharmaceutical players and global centers for drug development. However, Asia Pacific is expected to grow at the fastest pace due to rising scientific talent, lower costs and growing pharma industry in China and India. Countries are attracting CMOs and CROs through industry-friendly policies to boost local manufacturing and clinical research. Key players:
Key players operating in the biopharmaceutical CMO and CRO market are Albemarle Corporation, Greenchemicals S.r.l., ICL, Jordan Bromine Company, Kingboard Holdings Limited, LANXESS, Novel Chem, Shandong Brother Sci. & Tech. Co., Ltd., Shandong Futong Chemical Co., Ltd. and Tianjin Changlu Hangu Saltern Co., Ltd. The market has flourished due to strategic collaborations between biopharma firms and major global players. Market leaders are investing in expansions using advanced technologies to strengthen capabilities across various stages of drug development. Get more insights on this topic: https://www.newsstatix.com/biopharmaceutical-cmo-and-cro-market-industry-insights-trends-biopharmaceutical-cmo-and-cro-market/
#Biopharmaceutical CMO And CRO#Biopharmaceutical CMO And CRO Market#Biopharmaceutical CMO And CRO Market size#Biopharmaceutical CMO And CRO Market share#Biopharmaceutical CMO And CRO Market demand#Biopharmaceutical CMO And CRO Market analysis
0 notes
Text
Downstream Processing Market Size, Latest Trends, Share, Growth Analysis, and Forecast 2032
Downstream processing is a crucial phase in biopharmaceutical production, focusing on the purification, separation, and refinement of biologically-derived products. Following upstream production, downstream processing ensures that biomolecules, such as proteins, enzymes, and antibodies, are extracted and purified to meet stringent quality standards. This multi-step process is essential in producing pharmaceuticals, vaccines, and biologics, as it guarantees product purity, safety, and efficacy. Downstream processing is integral to biomanufacturing, supporting the delivery of high-quality products to meet growing global healthcare demands.
The Downstream Processing Market Size was valued at USD 35.89 billion in 2023, and is expected to reach USD 109.78 billion by 2031 and grow at a CAGR of 15% over the forecast period 2024-2031.
Future Scope
The future of downstream processing lies in advancements that streamline workflows, reduce production costs, and increase yields. Innovations such as continuous processing and single-use technologies are gaining momentum, offering scalable solutions that improve efficiency. Furthermore, integration with advanced analytics and automated control systems is expected to enhance process control and consistency, allowing for real-time quality monitoring. These developments are vital for addressing the rising demand for biopharmaceuticals while maintaining high standards and regulatory compliance.
Trends
Current trends in downstream processing include the adoption of single-use systems, which reduce cross-contamination risks and streamline cleaning procedures, and the shift toward continuous processing, which allows for uninterrupted production. Advanced purification techniques, such as membrane filtration and affinity chromatography, are also becoming standard practice, enabling faster and more efficient product refinement. Additionally, there is a strong focus on integrating digital monitoring and control systems to optimize every stage of the process.
Applications
Downstream processing is applied in the production of vaccines, therapeutic antibodies, hormones, and other biologic drugs. It is crucial in purifying cell cultures and separating target biomolecules from complex mixtures. This process is also used in diagnostics, gene therapy, and recombinant protein production, where it ensures the safety and efficacy of the final products. Due to its role in refining biologics, downstream processing is essential in meeting the rigorous standards of the pharmaceutical and biotechnology industries.
Key Points
Downstream processing refines biologically-derived products to ensure purity and safety.
Future developments focus on continuous processing, single-use technologies, and automation.
Trends include advanced purification techniques and digital monitoring systems.
Essential in producing vaccines, biologics, diagnostics, and gene therapies.
Plays a crucial role in biopharmaceutical production to meet regulatory standards.
Conclusion
Downstream processing is the backbone of biopharmaceutical production, enabling the industry to deliver safe, effective, and high-quality biologics. As technological advancements drive efficiency and scalability, downstream processing will continue to support the growth of biomanufacturing, facilitating the rapid development and production of vital therapeutics. This essential process stands at the forefront of innovation in biopharmaceuticals, ensuring the healthcare sector meets the demands for advanced and accessible treatments.
#Downstream Processing Market#Downstream Processing Market Size#Downstream Processing Market Share#Downstream Processing Market Growth#Downstream Processing Market Report
0 notes
Text
Exploring the Laboratory Filtration Market: Trends, Applications, and Future Growth
Market Overview
The global laboratory filtration market is projected to grow from USD 2.88 billion in 2024 to USD 4.20 billion by 2029, reflecting a CAGR of 6.81% over the forecast period (2024-2029). This growth is primarily driven by increasing demands in biopharmaceutical research, heightened quality standards for laboratory processes, and technological advancements in filtration systems. Expanding applications in fields such as nanotechnology, environmental analysis, and clinical diagnostics are also significant contributors to this market’s expansion.
Key Market Drivers
Growing Biopharmaceutical Research: Biopharmaceutical research and drug development are primary market drivers, as these fields require precise filtration for culture media preparation, sterilization, and sample purification.
Stringent Quality Standards: Regulatory standards for contamination control in laboratory processes are pushing for higher-quality filtration systems. As labs strive for compliance, demand for advanced filtration products increases.
Rise of Nanotechnology Applications: Nanotechnology requires highly specialized filtration solutions to handle nanoscale particles. This trend is pushing the industry toward developing filtration products with ultrafine pore sizes.
Advances in Microfiltration and Ultrafiltration: Microfiltration and ultrafiltration technologies are experiencing growth as they offer solutions to a range of lab needs, from separating microorganisms to concentrating proteins, aligning with the rise of protein-based research and analysis.
Geographic Insights
The demand for laboratory filtration solutions is particularly high in North America and Europe, with Asia-Pacific emerging rapidly due to increased research activities and investments in biotech sectors. The United States holds a significant market share due to its established pharmaceutical sector, while countries like India and China are growing as they boost their research infrastructure.
Key Players in the Market
Major companies in the laboratory filtration industry include Merck Millipore, Thermo Fisher Scientific, Sartorius AG, and Pall Corporation. These companies drive innovation through investments in research, focusing on advanced filtration technologies that meet evolving industry standards.
Conclusion
The laboratory filtration market is positioned for steady growth, supported by advancements in biopharmaceutical research, increasing regulatory standards, and new applications in nanotechnology. With continuous innovation, this industry is set to provide labs with the tools they need to enhance the purity and accuracy of their research outputs, ultimately impacting various sectors from healthcare to environmental analysis.
For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence: https://www.mordorintelligence.com/industry-reports/laboratory-filtration-market
#Laboratory Filtration Market#Laboratory Filtration Market Size#Laboratory Filtration Market Share#Laboratory Filtration Market Trends
0 notes
Text
Clinical Trials Market Comprehensive Analysis and Future Estimations by 2030
In 2023, the global clinical trials market was valued at USD 80.7 billion and is anticipated to grow at a compound annual growth rate (CAGR) of 6.49% from 2024 to 2030. Market growth was notably influenced by the COVID-19 pandemic, which in 2020 led to increased demand for both virtual and traditional clinical trials. Many companies made significant investments in developing new drugs to alleviate the burden of COVID-19 on healthcare systems. For instance, Synairgen plc and Parexel partnered on a Phase III study in 2020 to test the effectiveness of Interferon-beta (IFN-beta) treatment for COVID-19 patients. Additionally, technological advancements, a rising incidence of chronic diseases, the globalization of clinical trials, increased demand for personalized medicine, and a growing reliance on Contract Research Organizations (CROs) for conducting research activities are all expected to contribute to market growth.
The COVID-19 pandemic also brought about changes in how clinical trials were conducted, with regulatory agencies such as the U.S. FDA, European Medicines Agency (EMA), National Institutes of Health (NIH), and China’s National Medical Products Administration issuing guidelines to support decentralized and virtual clinical trials during the pandemic. This shift, along with the urgent need for new treatments, led to the adoption of fast-track clinical trials, providing new growth opportunities for the clinical trials market.
Gather more insights about the market drivers, restrains and growth of the Clinical Trials Market
Supportive government initiatives are another driver of market growth. For example, the World Health Organization (WHO) launched the Solidarity trial, an international effort to evaluate potential treatments for COVID-19 by comparing four treatments against the standard of care. In May 2020, WHO also announced an international coalition to develop multiple vaccine candidates simultaneously, naming this effort the Solidarity trial for vaccines.
Moreover, the increasing use of CRO services allows manufacturers and sponsors to focus on production capabilities and enhance in-house processes. CROs offer a wide range of services from drug discovery to post-marketing surveillance, which has simplified operations for small and mid-sized pharmaceutical and biotech companies by allowing them to outsource R&D activities, reducing infrastructure costs. For example, in November 2023, Syneos Health entered into an agreement with GoBroad Healthcare Group, expanding its clinical trial capabilities across multiple therapeutic areas in China.
Sponsors Segmentation Insights:
In 2023, pharmaceutical and biopharmaceutical companies accounted for the largest revenue share in the clinical trials market. This dominance is due to the industry’s high level of interest and financial investment in drug research and development. While basic research in academic labs is primarily funded by grants from the National Institutes of Health (NIH), the pharmaceutical industry bears the substantial costs associated with discovering and testing new drugs on animals and humans. Clinical trials represent a major expense, with the cost to bring a new drug to market ranging from USD 266 million to USD 802 million. In the U.S., approximately 75% of clinical trial funding comes from corporate sponsors.
The patient recruitment and retention segment captured a significant market share in 2023. The growing number of clinical studies worldwide has increased the demand for patient recruitment services. Increased funding for clinical research and widespread adoption of digital technologies are further supporting this growth. The market expansion is also driven by large investments in R&D, government support, and the presence of major CROs that provide comprehensive services, including patient recruitment, with active participation from multinational pharmaceutical and biopharmaceutical companies.
The data management segment also held a notable share in 2023 and is expected to maintain this trend over the forecast period. Growth in this segment is driven by the increasing adoption of data management services and a trend toward decentralized trials. The integration of advanced technologies like Artificial Intelligence (AI) and Machine Learning (ML) for data entry, analysis, and quality control is further expected to drive demand in this segment.
Order a free sample PDF of the Clinical Trials Market Intelligence Study, published by Grand View Research.
0 notes